Cargando…

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis

OBJECTIVES: A few studies on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treatments have shown the therapeutic efficacy of mycophenolate mofetil (MMF). However, the therapeutic efficacy of MMF compared with that of cyclophosphamide (CYC) in patients with AAV has not been e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuzuya, Kentaro, Morita, Takayoshi, Kumanogoh, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299518/ https://www.ncbi.nlm.nih.gov/pubmed/32371435 http://dx.doi.org/10.1136/rmdopen-2020-001195

Ejemplares similares

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Prendecki, Maria, et al.
Publicado: (2022)

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2019)

Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study
por: Merindol, Julie, et al.
Publicado: (2023)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis
por: Koukoulaki, Maria, et al.
Publicado: (2019)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
por: Xiong, Anji, et al.
Publicado: (2021)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Phosphatidylinositol 3‐Kinase δ Deficiency Protects From Antimyeloperoxidase Vasculitis
por: Flórez‐Barrós, Fernanda, et al.
Publicado: (2022)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study
por: Mimura, Norihiro, et al.
Publicado: (2023)

Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study
por: Besutti, Giulia, et al.
Publicado: (2022)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study
por: Aiyegbusi, Oshorenua, et al.
Publicado: (2021)

VEXAS Syndrome: A Case Series From a Single‐Center Cohort of Italian Patients With Vasculitis
por: Muratore, Francesco, et al.
Publicado: (2022)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
por: Casal Moura, Marta, et al.
Publicado: (2023)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
por: Águeda, Ana F, et al.
Publicado: (2019)

Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: a matched cross-sectional study
por: Besutti, Giulia, et al.
Publicado: (2023)

Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening
por: Xu, Tingting, et al.
Publicado: (2022)

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
por: Chrysidis, Stavros, et al.
Publicado: (2018)

Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
por: Hogan, Susan L., et al.
Publicado: (2019)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Teixeira, Vítor, et al.
Publicado: (2019)

A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis
por: Philobos, Mariana, et al.
Publicado: (2021)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool
por: Sebastian, Alwin, et al.
Publicado: (2020)

Antineutrophilic Cytoplasmic Antibody Positive Vasculitis Associated with Methimazole Use
por: Shikha, Deep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_30c7556e7oegsdff69npncfg89